Long-term therapy with inhaled iloprost in patients with pulmonary hypertension
Aims - To investigate the long-term safety of inhaled iloprost in patients with pulmonary hypertension (pH), including idiopathic PAH (IPAH group) and other forms of pulmonary hypertension (PHother). - Methods and results - Sixty-three patients (IPAH group, n=40, PHother n=23) were enrolled to recei...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
11 February 201
|
| In: |
Respiratory medicine
Year: 2010, Volume: 104, Issue: 5, Pages: 731-740 |
| ISSN: | 1532-3064 |
| DOI: | 10.1016/j.rmed.2010.01.008 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.rmed.2010.01.008 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0954611110000156 
|
| Author Notes: | Horst Olschewski, Marius M. Hoeper, Juergen Behr, Ralf Ewert, Andreas Meyer, Mathias M. Borst, Jörg Winkler, Michael Pfeifer, Heinrike Wilkens, Hossein Ardeschir Ghofrani, Sylvia Nikkho, Werner Seeger |
| Summary: | Aims - To investigate the long-term safety of inhaled iloprost in patients with pulmonary hypertension (pH), including idiopathic PAH (IPAH group) and other forms of pulmonary hypertension (PHother). - Methods and results - Sixty-three patients (IPAH group, n=40, PHother n=23) were enrolled to receive inhaled iloprost either from baseline or after 3 months in a prospective, open-label 2-year study. Iloprost was inhaled 6-9 times daily with a night pause employing a jet nebulizer delivering an inhaled single dose of 4μg at the mouthpiece. In the case of side effects the single dose was reduced to 2μg. Sixty patients received at least 1 dose of inhaled iloprost. Thirty-six patients completed at least 630 days of therapy (25 IPAH, 11 PHother), 19 patients dropped out prematurely and 8 patients died (3 IPAH, 5 PHother). There were no drug-induced toxicities and only mild to moderate side effects. The most common side effects were coughing and flushing. Two-year survival was estimated at 85% (IPAH group 91%, PHother 78%). A modified analysis was performed to correct for differential drop-out. It included follow-up data from the premature discontinuations and revealed a 2-year survival of 87% [95% CI, 76%-98%] in the IPAH group while the predicted survival was 63%. The iloprost dose increased by 16% over 2 years. - Conclusion - Inhaled iloprost is well tolerated as long-term therapy and no substantial dose increase is required. Although uncontrolled, the data suggest a long-term clinical benefit from continued therapy with inhaled iloprost. |
|---|---|
| Item Description: | Gesehen am 14.06.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1532-3064 |
| DOI: | 10.1016/j.rmed.2010.01.008 |